<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7905840</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6445</journal-id>
<journal-id journal-id-type="nlm-ta">Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Ther.</journal-id>
<journal-title-group>
<journal-title>Pharmacology &amp; therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0163-7258</issn>
<issn pub-type="epub">1879-016X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26627987</article-id>
<article-id pub-id-type="pmc">4747781</article-id>
<article-id pub-id-type="doi">10.1016/j.pharmthera.2015.11.012</article-id>
<article-id pub-id-type="manuscript">NIHMS741258</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ghaisas</surname>
<given-names>Shivani</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maher</surname>
<given-names>Joshua</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kanthasamy</surname>
<given-names>Anumantha</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">‡</xref>
</contrib>
<aff id="A1">Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, Iowa 50011, USA</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>‡</label>To whom correspondence should be addressed: Dept. of Biomedical Sciences, Iowa State University, 2062 College of Veterinary Medicine Building, Ames, IA 50011. Tel: 515-294-2516; Fax: 515-294-2315; <email>akanthas@iastate.edu</email></corresp>
<fn fn-type="conflict" id="FN2">
<p><bold>Conflict of Interest</bold>: A.G.K. is a shareholder of PK Biosciences Corporation (Ames, IA), which is interested in translating mechanistic studies into therapies targeting kinase signaling. The other authors have no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>158</volume>
<fpage>52</fpage>
<lpage>62</lpage>
<!--elocation-id from pubmed: 10.1016/j.pharmthera.2015.11.012-->
<abstract>
<p id="P2">The gut microbiome comprises the collective genome of the trillions of microorganisms residing in our gastrointestinal ecosystem. The interaction between the host and its gut microbiome is a complex relationship whose manipulation could prove critical to preventing or treating not only various gut disorders, like irritable bowel syndrome (IBS) and ulcerative colitis (UC), but also central nervous system (CNS) disorders, such as Alzheimer’s and Parkinson’s diseases. The purpose of this review is to summarize what is known about the gut microbiome, how it is connected to the development of disease and to identify the bacterial and biochemical targets that should be the focus of future research. Understanding the mechanisms behind the activity and proliferation of the gut microbiome will provide us new insights that may pave the way for novel therapeutic strategies.</p>
</abstract>
<kwd-group>
<kwd>microbiome-gut-brain axis</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>gut microbiota</kwd>
<kwd>neurological diseases</kwd>
<kwd>Autism</kwd>
<kwd>manganese</kwd>
<kwd>metals</kwd>
<kwd>environmental factors</kwd>
<kwd>neurotoxicity</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>